Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial

https://www.thelancet.com/collections/neurology?dgcid=hubspot_email_infocusalerts-neurology_feature&parent=001585&startPage=&ContentItemType=fla&utm_campaign=infocusalerts-neurology&utm_medium=email&_hsenc=p2ANqtz-9xD6eaLkLlhGbuaniAttgvbNe5KrXnKiCslQkQ86xiwAsnppWh9Sz6ihNKBBY1gPOVm4IJtHd2kmeQmgrgBL3qccDxkg&_hsmi=378214547&utm_content=374294590&utm_source=hs_email